Absolute risk reduction may depend on the duration of the follow-up by Ferenci, Tamás
Expert Rev Clin Pharmacol. 2015 Nov 2:1-2. 
Absolute risk reduction may depend on 
the duration of the follow-up 
Tamás Ferenci 
 
Title: Absolute risk reduction may depend on the duration of the follow-up 
Author name and affiliation: Tamás Ferenci, Óbuda University, John von Neumann Faculty of 
Informatics, Physiological Controls Group, Address: Budapest, Hungary, H-1034 Bécsi út 96/b, Phone 
number: +36 (1) 666-5553, Fax number: +36 (1) 666-5522, e-mail address: ferenci.tamas@nik.uni-
obuda.hu. 
Article type: Letter to the Editor 
 
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical 
Pharmacology on 02 Nov 2015, available online: http://dx.doi.org/10.1586/17512433.2015.1102008. 
  
Dear Editor, 
 
I have read the paper titled ‘How statistical deception created the appearance that statins are safe 
and effective in primary and secondary prevention of cardiovascular disease’ in your journal [1] with 
great interest. 
As a biostatistician, I don’t want (and cannot) to comment on the pharmacological aspects raised in 
the paper. However, one of the most emphasized points raised by the authors is – statistically – 
unfounded in my opinion. 
The authors argue that absolute risk reduction (ARR) (or its reciprocal, the number needed to treat 
(NNT) ) should have been used instead of relative risk in presenting the results of the trials they have 
reviewed. They even state that this was an intentional decision to deceive the readers. While I can’t 
speak about the intentions of those presenting the results of these studies, the authors are 
methodologically wrong in their first claim. The application of relative risk is correct, and the 
application of ARR would have been incorrect. 
The problem with absolute risk reduction – and therefore with NNT too – is that it depends on the 
length of the follow-up, [2-4] should the risk of the disease accumulate over time (which is clearly the 
case for cardiovascular diseases). The relative risk is constant in this sense (apart from the possible 
time-varying treatment effectiveness), but how it translates to risk difference depends on the risk of 
the control group, that is, the baseline (background) risk, which in turn depends on how long we 
observe it. 
Let us examine a concrete example to illustrate this. Assuming an incidence of 1%/year (just to 
provide a numerically simple example) without treatment, the risk in the control group will be 1% in 
1 year. Assuming a treatment effectiveness of 50%, this translates to an absolute risk reduction of 
0.5%points (NNT=200). In 2 years, with the effectiveness remaining completely constant, the 
incidence raises to 1.99% in the control group, and 0.995% in the treatment group 
(ARR=0.995%points, NNT=100.5). In 5 years, we have a risk of 4.9% and 2.45% (ARR=2.45%points, 
NNT=40.8). In 10 years, we have an NNT of 20.9, in 20 years, 11. Thus, the metrics suggested by the 
authors change over time, in other words, depend on the length of the follow-up – while the actual 
effectiveness of the drug is constant! 
This is actually the very reason why the usage of relative risk makes sense: we can extrapolate, at 
least when assuming a time-invariant treatment effect, even if the study had a duration that is 
shorter than the clinically realistic duration of the treatment with the drug. 
Therefore, the application of ARR and NNT is only valid if the length of the follow-up is comparable to 
the risk period. However, quite the opposite is true in our case: the relevant time horizon for the 
onset of cardiovascular diseases can be measured in decades, while the cited trials had a follow-up of 
years. The application of ARR or NNT in this case is clearly inappropriate. 
This issue has been described decades ago in the literature (see, e.g., the discussion of [5]). 
To put my remarks into a broader context, the authors are actually right that for many purposes, ARR 
is the useful indicator (to evaluate the public health impact of the intervention, to judge side effects 
etc.), [6-7] and the application of relative risk may indeed be unfortunate or even misleading in these 
cases. [8] We nevertheless have to keep in mind that ARR is a derived indicator: it is the product of 
relative risk (a property of the drug) and the baseline risk (property of the disease). A drug trial 
should – of course – measure what is characteristic for the drug. It would be not only unnecessary, 
but downright harmful to measure only a “composite” indicator (it would, for instance, prevent us 
from assessing the drug’s effectiveness in another country, with different disease risk); we should 
rather measure the “components”. The authors are right that users of these results should place 
them into context (e.g., start with calculating ARR for their own country), and due to this exact 
reason, the original publications should also report ARRs. But if the authors consider the presented 
ARRs to be “miniscule”, even that means that the risk of the disease, and not the drug’s effectiveness 
is exaggerated. (However, like I have warned beforehand, it is quite questionable in my opinion to 
judge the risk of a cardiovascular disease based on trials having only a few years of follow-up.) 
To sum up: what the authors label as “statistical deception” is in fact the statistically sound approach, 
and what they suggest as statistically correct approach would be – ironically – deceptive. 
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